We protect your health through science
Investigation
Immune Pathogenesis and Viral Reservoir
Research Lines
Content with Investigacion .
Caracterización molecular de los estafilococcus
El Laboratorio de Referencia e investigación en Infecciones Relacionadas con la Asistencia Sanitaria dispone de un Programa de Vigilancia de Staphylococcus aureus y Estafilococos coagulasa negativa y de la siguiente cartera de servicios:
Estafilococos coagulasa negativa
Identificación:
Por secuencia del gen 16S del ARN ribosómico
Por secuencia del gen rpoB
Por secuencia del gen tuf
Marcadores moleculares
Perfil por PFGE
SSC
mec
MLST
Detección de genes
Genes mec
Genes de resistencia
Mecanismos de resistencia al linezolid
Dominio V del gen 23S ARNr
Gen rplC (riboproteína L3)
Gen rplD (riboproteína L4)
Gen rplV (riboproteína L22)
Staphylococcus aureus
Identificación:
PCR del gen Sau
Por secuencia del gen 16S del ARN ribosómico
Por secuencia del gen rpoB
Por secuencia del gen tuf
Marcadores moleculares
PFGE
MLST
SSC
mec
Spa-tipo
Detección de genes
Genes mec
Gen PVL
Toxinas exfoliativas (SST)
Toxina del Shock Tóxico (TSST)
Research projects
Content with Investigacion .
En el Laboratorio de I.R.A.S., también denominado de "Infecciones Intrahospitalarias", nos centramos actualmente en la caracterización molecular de los estafilococos, tanto S. aureus, como coagulasa negativos.
Los marcadores moleculares habituales, en el caso de los S. aureus son: electroforesis en campo pulsado (PFGE), tipificación multilocus de secuencias (MLST), tipo de casete cromosómico estafilocócico (SSCmec), tipificación spa, También detectamos, entre otros, los genes mec y PVL, los genes que codifican la Toxina exfoliativa (SST) y la Toxina del Shock Tóxico. Asimismo, para la identificación de los estafilococos coagulasa negativos, secuenciamos los genes 16S, rpoB, tuf., a los que también aplicamos PFGE, SSCmec, MLST.
Nuestras líneas de investigación se centran, por un lado, en el estudio de los mecanismos de resistencia a las oxazolidinonas: gen cfr, dominio del gen 23S ARNr , gen rplC (riboproteína L3), gen rplD (riboproteína L4), gen rplV (riboproteína L22). Hemos detectado, por primera vez, la existencia de nuevas mutaciones en la riboproteína L4 en un paciente con fibrosis quística. Aparte de los estudios llevados a cabo de las resistencias al linezolid en distintos hospitales, estudiamos en colaboración con la Universidad de Tsukuba (Japón) y la Universidad Europea la prevalencia del plásmido pSCFS7 entre cepas cfr positivas de distintos hospitales españoles.
Por otra parte, participamos en estudios multicéntricos (2002-2014) para conocer mejor el estado de la población estafilocócica española, centrándonos fundamentalmente en las cepas de S. aureus resistentes a meticilina (SARM); dado que es un importante patógeno humano que causa una amplia variedad de infecciones que pueden ser leves, como algunas infecciones de piel y partes blandas, o graves, como bacteriemia, endocarditis, neumonía e infecciones de localización quirúrgica. Además, pueden producir una colonización asintomática, lo que facilita su transmisión y diseminación. Desde su descripción inicial en 1959 y durante varias décadas, el SARM se había considerado un patógeno confinado al ámbito sanitario, pero a partir de la década de los noventa, se describe la emergencia de cepas SARM responsables de infecciones aparentemente adquiridas en la comunidad.
Dentro de esta línea estamos colaborando en el proyecto: "Colonización por S. aureus resistente a la meticilina en niños sanos de la comunidad (estudio C.O.S.A.C.O.)", que es un estudio multicéntrico de ámbito nacional.
También colaboramos con otros laboratorios en distintos estudios, como: "Mecanismos de patogenicidad y protección en bacterias Gram positivas causantes de enfermedades respiratorias y bacteriemia".
Publications
Prevalence and genotype identification of Toxoplasma gondii in wild animals from southwestern Spain.
8. Calero-Bernal R, Saugar JM, Frontera E, Pérez-Martín JE, Habela MA, Serrano FJ, Reina D, Fuentes I. 2015. Prevalence and genotype identification of Toxoplasma gondii in wild animals from southwestern Spain. J Wildl Dis, 51:233-8.
PUBMED DOIHigh SARS-CoV-2 Viral Load and Low CCL5 Expression Levels in the Upper Respiratory Tract Are Associated With COVID-19 Severity.
4. Pérez-García F, Martin-Vicente M, Rojas-García RL, Castilla-García L, Muñoz-Gomez MJ, Hervás-Fernández I, González-Ventosa V, Vidal-Alcántara EJ, Cuadros-González J, Bermejo-Martin JF (‡), Resino S (‡ *), Martínez I (‡). High SARS-CoV-2 Viral Load and Low CCL5 Expression Levels in the Upper Respiratory Tract Are Associated With COVID-19 Severity. J Infect Dis 2022; 225(6):977-982 (A; FI= 7.76; Q1, Infectious Diseases; JCR 2021). PMID: 34910814 DOI: 10.1093/infdis/jiab604.
PUBMED DOIMetabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.
5. Virseda-Berdices A, Rojo D, Martínez I, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Pérez-Latorre L, Micán R, Barbas C, Resino S (‡ *), Jiménez-Sousa MA (‡ *). Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomed Pharmacother 2022, 147: 112626. (A; FI= 7.42; D1, Pharmacology & Pharmacy; JCR 2021).
PUBMED DOIBlood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis.
7. Virseda-Berdices A, Brochado-Kith O, Díez C, Hontañon V, Berenguer J, González-García J, Rojo D, Fernández-Rodríguez A, Ibañez-Samaniego L, Llop-Herrera E, Olveira A, Perez-Latorre L, Barbas C, Rava M (‡), Resino S (‡ *), Jiménez-Sousa MA (‡ *). Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis. J Antimicrob Chemoth 2022; 77 (3): 719–726 (A; FI= 5.76; Q1, Pharmacology & Pharmacy; JCR 2020).
PUBMED DOIA Q Fever Outbreak with a High Rate of Abortions at a Dairy Goat Farm: Coxiella burnetii Shedding, Environmental Contamination, and Viability
3. Álvarez-Alonso R, Basterretxea M, Barandika JF, Hurtado A, Idiazabal J, Jado I, Beraza X, Montes M, Liendo P, García-Pérez AL. A Q Fever Outbreak with a High Rate of Abortions at a Dairy Goat Farm: Coxiella burnetii Shedding, Environmental Contamination, and Viability. Appl Environ Microbiol. 2018 Oct 1;84(20).
PUBMED DOIIrruptive mammal host populations shape tularemia epidemiology.
4. Luque-Larena, Juan J.; Mougeot, Francois; Arroyo, Beatriz; Dolors Vidal, Ma; Rodriguez-Pastor, Ruth; Escudero, Raquel; Anda, Pedro; Lambin, Xavier. Irruptive mammal host populations shape tularemia epidemiology. Plos Pathogens. 13 - 11, Public Library Science, 01/11/2017.
PUBMED DOIEnvironmental sampling coupled with real-time PCR and genotyping to investigate the source of a Q fever outbreak in a work setting.
5. Hurtado A, Alonso E, Aspiritxaga I, López Etxaniz I, Ocabo B, Barandika JF, Fernández-Ortiz DE Murúa JI, Urbaneja F, Álvarez-Alonso R, Jado I, García-Pérez AL. Environmental sampling coupled with real-time PCR and genotyping to investigate the source of a Q fever outbreak in a work setting. Epidemiol Infect. 2017 Jul;145(9):1834-1842.
PUBMED DOIDensity-Dependent Prevalence of Francisella tularensis in Fluctuating Vole Populations, Northwestern Spain
6. Rodriguez-Pastor, Ruth; Escudero, Raquel; Vidal, Dolors; Mougeot, Francois; Arroyo, Beatriz; Lambin, Xavier; Maria Vila-Coro, Ave; Rodriguez-Moreno, Isabel; Anda, Pedro; Luque-Larena, Juan J.Density-Dependent Prevalence of Francisella tularensis in Fluctuating Vole Populations, Northwestern Spain. Emerging Infectious Diseases. 23 - 8, pp. 1377 - 1379. Centers Disease Control, 01/08/2017.
PUBMED DOIGenotypes of Coxiella burnetii in wildlife: disentangling the molecular epidemiology of a multi-host pathogen
7. González-Barrio D, Jado I, Fernández-de-Mera IG, Del Rocio Fernández-Santos M, Rodríguez-Vargas M, García-Amil C, Beltrán-Beck B, Anda P, Ruiz-Fons F. Genotypes of Coxiella burnetii in wildlife: disentangling the molecular epidemiology of a multi-host pathogen. Environ Microbiol Rep. 2016 Oct;8(5):708-714.
PUBMED DOIDevelopment of Improved Serodiagnostics for Tularemia by Use of Francisella tularensis Proteome Microarrays
8. Nakajima, Rie; Escudero, Raquel; Molina, Douglas M.; Rodriguez-Vargas, Manuela; Randall, Arlo; Jasinskas, Algis; Pablo, Jozelyn; Felgner, Philip L.; AuCoin, David P.; Anda, Pedro; Davies, D. Huw. Towards Development of Improved Serodiagnostics for Tularemia by Use of Francisella tularensis Proteome Microarrays. Journal of Clinical Microbiology. 2016 Jul;54(7):1755-1765.
PUBMED DOIInterruption of onchocerciasis transmission in Bioko Island: Accelerating the movement from control to elimination in Equatorial Guinea
5. Herrador Z, Garcia B, Ncogo P, Perteguer MJ, Rubio JM, Rivas E, Cimas M, Ordoñez G, de Pablos S, Hernández-González A, Nguema R, Moya L, Romay-Barja M, Garate T, Barbre K, Benito A. Interruption of onchocerciasis transmission in Bioko Island: Accelerating the movement from control to elimination in Equatorial Guinea. PLoS Negl Trop Dis. 2018 May 3;12(5):e0006471.
PUBMED DOILAMP kit for diagnosis of non-falciparum malaria in Plasmodium ovale infected patients
7. Thuy-Huong Ta-Tang, Sergio L. B. Luz, Francisco J. Merino, Isabel de Fuentes, Rogelio López-Vélez, Tatiana A. P. Almeida, Marta Lanza, Cláudia M. M. Abrahim, and José M. Rubio (2016). Atypical Mansonella ozzardi Microfilariae from an Endemic Area of Brazilian Amazonia. Am. J. Trop. Med. Hyg 95(3), 2016, pp. 633–636.
PUBMED DOIComparison of Imported Plasmodium ovale curtisi and P. ovale wallikeri Infections among Patients in Spain, 2005-2011.
9. Rojo-Marcos G, Rubio-Muñoz JM, Ramírez-Olivencia G, García-Bujalance S, Elcuaz-Romano R, Díaz-Menéndez M, Calderón M, García-Bermejo I, Ruiz-Giardín JM, Merino-Fernández FJ, Torrús-Tendero D, Delgado-Iribarren A, Ribell-Bachs M,Arévalo-Serrano J, Cuadros-González J (2014). Comparison of Imported Plasmodium ovale curtisi and P. ovale wallikeri Infections among Patients in Spain, 2005-2011. Emerg Infect Dis. 2014 Mar;20(3):409-16.
PUBMED DOIArbovirus surveillance: first dengue virus detection in local Aedes albopictus mosquitoes in Europe, Catalonia, Spain, 2015.
1. C Aranda; MJ Martínez; T Montalvo; R Eritja; J Navero-Castillejos; E Herreros; E Marqués; R Escosa; I Corbella; E Bigas; L Picart; M Jané; I Barrabeig; N Torner; S Talavera; Ana Vázquez; María Paz Sánchez-Seco; Nuria Busquets. Arbovirus surveillance: first dengue virus detection in local Aedes albopictus mosquitoes in Europe, Catalonia, Spain, 2015.Eurosurveillance. 23 - 47, 2018.
PUBMED DOIPhylogenetic Characterization of Crimean-Congo Hemorrhagic Fever Virus, Spain
2. Eva Ramírez de Arellano; Lourdes Hernández; M José Goyanes; Marta Arsuaga; Ana Fernández Cruz; Anabel Negredo; María Paz Sánchez Seco. Phylogenetic Characterization of Crimean-Congo Hemorrhagic Fever Virus, Spain. Emerging infectious diseases. 23 - 12, pp. 2078 - 2080. 12/2017. ISSN 1080-6059
PUBMED DOIToscana virus infection in Catalonia (Spain).
4. Neus Cardeñosa; Diana Kaptoul; Pedro Fernández Viladrich; Carles Aranda; Fernando de Ory; Jordi Niubó; Pere Plans; Angela Domínguez; Giovanni Fedele; Antonio Tenorio; María Paz Sánchez Seco. Toscana virus infection in Catalonia (Spain). Vector borne and zoonotic diseases (Larchmont, N.Y.). 13 - 4, pp. 273 - 278. 04/2013. ISSN 1557-7759
PUBMED DOI. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain
5. Anabel Negredo; Fernando de la Calle Prieto; Eduardo Palencia Herrejón; Marta Mora Rillo; Jenaro Astray Mochales; María P Sánchez Seco; Esther Bermejo Lopez; Javier Menárguez; Ana Fernández Cruz; Beatriz Sánchez Artola; Elena Keough Delgado; Eva Ramírez de Arellano; Fátima Lasala; Jakob Milla; Jose L Fraile; Maria Ordobás Gavín; Amalia Martinez de la Gándara; Lorenzo López Perez; Domingo Diaz Diaz; M Aurora López García; Pilar Delgado Jimenez; Alejandro Martín Quirós; Elena Trigo; Juan C Figueira; Jesús Manzanares; Elena Rodriguez Baena; Luis Garcia Comas; Olaia Rodríguez Fraga; Nicolás García Arenzana; Maria V Fernández Díaz; Victor M Cornejo; Petra Emmerich; Jonas Schmidt Chanasit; Jose R Arribas. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain.The New England journal of medicine. 377 - 2, pp. 154 - 161. 13/07/2017. ISSN 1533-4406
PUBMED DOIZika Virus Screening among Spanish Team Members After 2016 Rio de Janeiro, Brazil, Olympic Games
6. Natalia Rodriguez Valero; Alberto M Borobia; Mar Lago; Maria Paz Sánchez Seco; Fernando de Ory; Ana Vázquez; Jose Luis Pérez Arellano; Cristina Carranza Rodríguez; Miguel J Martínez; Alicia Capón; Elias Cañas; Joaquin Salas Coronas; Arkaitz Azcune Galparsoro; Jose Muñoz. Zika Virus Screening among Spanish Team Members After 2016 Rio de Janeiro, Brazil, Olympic Games. Emerging infectious diseases. 23 - 8, pp. 1426 - 1428. 08/2017. ISSN 1080-6059
PUBMED DOIProlonged Zika Virus Viremia during Pregnancy
7. Anna Suy; Elena Sulleiro; Carlota Rodó; Élida Vázquez; Cristina Bocanegra; Israel Molina; Juliana Esperalba; María P Sánchez Seco; Hector Boix; Tomás Pumarola; Elena Carreras. Prolonged Zika Virus Viremia during Pregnancy. The New England journal of medicine. 375 - 26, pp. 2611 - 2613. 29/12/2016. ISSN 1533-4406
PUBMED DOIAdditional Information
Contact Information
María Teresa Coiras
918223782
mcoiras@isciii.es
generic email: pirv.isciii@gmail.com
Scientific Societies
• Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
• AIDS Study Group (GeSIDA) of SEIMC.
• PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).
Other links
You can follow the activity of our group in Twitter (X), Instagram and Linkedin.
Collaboration in other projects
Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections. Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545
Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024
Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924
Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025
Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006
Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22
Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006
Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877
Contact Information
María Teresa Coiras
918223782
mcoiras@isciii.es
generic email: pirv.isciii@gmail.com
Scientific Societies
• Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
• AIDS Study Group (GeSIDA) of SEIMC.
• PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).
Other links
You can follow the activity of our group in Twitter (X), Instagram and Linkedin.
Collaboration in other projects
Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections. Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545
Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024
Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924
Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025
Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006
Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22
Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5
Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006
Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877